HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cubo, E. Articles by Leurgans, S. E. Search for Related Content PubMed PubMed Citation Articles by Cubo, E. Articles by Leurgans, S. E.

Effect of donepezil on motor and cognitive function in Huntington disease

From the Movement Disorders Unit, Neurology Department, Rush University Medical Center, Chicago, IL (E.C., K.M.S., D.T., J.A.J., B.A.B., J.W., S.E.L.); and Movement Disorders Unit, Neurology Department, Hospital General Yagüe, Burgos, Spain (E.C.).

Address correspondence and reprint requests to Dr. Esther Cubo, Calle Albox 4, 1F, Madrid, 28025, Spain; e-mail: estercub{at}wanadoo.es

Striatal cholinergic dysfunction may be important in Huntington disease (HD). We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD. Thirty patients were randomly assigned to treatment with donepezil or placebo. At the doses studied, donepezil did not improve chorea, cognition, or QoL. Adverse events were similar between both groups. Based on this small sample study, donepezil was not an effective treatment for HD.

This study received financial support from Pfizer-Eisai Inc.

Disclosure: The authors report no conflicts of interest.

Received September 23, 2005. Accepted in final form June 14, 2006.